{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-156571","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2023-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.286760+00:00","generated_at":"2026-06-14T11:49:10.554588+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Finch Therapeutics enters consulting agreement with former CEO Mark Smith; up to $150K performance pay","bullets":["Consulting agreement with former CEO Mark Smith effective May 25, 2023 for advisory services.","Compensation includes hourly cash rate and eligibility for performance-based cash payments.","Maximum aggregate performance payments of $150,000 tied to critical corporate objectives.","Performance metrics determined by Compensation Committee of Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-156571","json":"https://secwatch.observer/filing/0001193125-23-156571.json","markdown":"https://secwatch.observer/filing/0001193125-23-156571.md","text":"https://secwatch.observer/filing/0001193125-23-156571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000119312523156571/0001193125-23-156571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000119312523156571/d431694d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T11:49:10.554588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}